Key Highlights

  • Ascendis Pharma (NASDAQ:ASND) reported third quarter product Revenue of EUR 366 million, up 89%, led by Yorvipath at EUR 291 million, up 103%.
  • IFRS operating profit reached EUR 125 million against EUR 11 million a year earlier, and net profit was EUR 74 million after a net loss of EUR 61 million.
  • Cash rose to EUR 964 million, and the company expects Operating Cash Flow of at least EUR 600 million for 2026.
  • The shares edged down 0.20% to USD 271.19 in the latest session and sit within about 4% of their 52-week high.

Yorvipath Drives a Profitable Quarter

Ascendis Pharma reported third quarter 2026 results on November 12. Total revenue was EUR 369.7 million against EUR 213.6 million a year earlier, and commercial product revenue rose 89% to EUR 365.7 million. Yorvipath, the treatment for hypoparathyroidism in adults, generated EUR 290.6 million, up 103% and about EUR 39 million above the second quarter. Skytrofa grew about 17% to EUR 59.4 million, and Yuviwel, the treatment for achondroplasia known in development as TransCon CNP, contributed EUR 15.6 million in its first full United States quarter, roughly double the previous quarter. IFRS operating profit was EUR 124.6 million, a 34% margin, and the non-IFRS figure was EUR 156 million, a 42% margin. Net profit was EUR 74.0 million, or EUR 1.08 per diluted share, against a loss of EUR 61.0 million. Net finance expense fell to EUR 4 million from EUR 61 million. Nine month net profit is far larger because of about EUR 615 million of tax income from recognised deferred tax assets, which investors should treat as non-operating.

Cash Builds and Buybacks Continue

The Balance Sheet has strengthened quickly. Operating cash flow was EUR 189 million in the quarter and EUR 463 million for nine months, including EUR 158 million from the sale of a priority review voucher. Cash and equivalents reached EUR 964.4 million at September 30 from EUR 616.0 million at the end of 2025, and the company expects 2026 operating cash flow of at least EUR 600 million. The board authorised repurchases of up to USD 400 million on September 14, and the company had bought 794,304 shares for USD 186 million by the end of September. By November 11 year to date repurchases totalled about 2.0 million shares for USD 459 million. Operating expenses rose to EUR 217 million from EUR 180 million as selling costs grew to support launches. Chief executive Jan Mikkelsen said the company sees three complementary drivers of durable growth, and management reiterated its goal of more than EUR 5 billion of product revenue in 2030.

Regulatory Progress and a Reset of the Obesity Strategy

Regulatory news has added to the momentum. On October 16 the European committee for medicinal products recommended approval of TransCon CNP for children with achondroplasia aged two and older, and on November 6 the company said it would receive ten years of market exclusivity in Europe once approved. A European Commission decision is expected in the fourth quarter, with a first European launch in Germany planned for the first quarter of 2027 under the Yuviwel brand. In the United States, about 340 patients had enrolled with nearly 150 prescribers by the end of October, and more than 80% had been approved for reimbursement. On September 14 the company announced it would regain exclusive rights to its TransCon technology in metabolic and cardiovascular indications after Novo Nordisk ended their collaboration, and it plans to advance once monthly TransCon semaglutide. Yorvipath is available in more than 40 countries, and phase 3 trials in hypochondroplasia and adult achondroplasia are expected to start in the fourth quarter.

Where Things Stand

Ascendis Pharma is near its 52-week high as Yorvipath growth, a profitable quarter and a fast build in cash support the shares. The European decision on TransCon CNP and the pace of the Yuviwel launch are the next catalysts.